Sheet

Under the Paper

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

Date Submitted: March 3, 2008

(use as many sheets as necessary)

MODIFIED PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0551-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

k Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Complete if Known 09/715,764 **Application Number** 11/15/2000 Filing Date **First Named Inventor Heinz-Josef LENZ** Group Art Unit 1634 **Examiner Name** Sitton, Jehanne Souaya Attorney Docket Number 064189-0201 (2924)

	U.S. PATENT DOCUMENTS								
Examiner Cite No.1	.	U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant			
		Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear			
70	1	5,705,336		Reed, et al.	01-06-1998				
90	2	6,716,581	B2	Lenz et al.	04-06-2004				
Q ₂	3	2004/0067519	A1	Lenz et al.	04-08-2004				
			·			· ·			
•									
-									

s, Lines, Ivant
Where Relevant Passages or Relevant Figures Appear
'

		FC	DREIGN PATENT DOCUMEN	TS	····	
Examiner Initials*	Cite No. ¹	Foreign Patent Document Office ³ Number ⁴ Kind Code ³ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	₽°
70	4	WO 01/36686	University of Southern California	05-25-2001		

Examiner Signature	Jehanne Sitt	Date Considered	10/6/06
AEVALUMED.			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ²Enter Office that issued the document, by the two-letter code (MIPO Standard ST.3). ⁴For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁰Applicant is to place a check mark here if English language

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

MAR 0 6 2006 Under the Papervio

k Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control o Under tr oumber.

PRADEWS	Substitute for fo	om 14498/	PTO		Complete if Known			
	INFORMATION			Application Number	09/715,764			
	STATEMENT (BY APPLI	CANT	Filing Date	11/15/2000			
	Date Submitted	d. March 3	2006	First Named Inventor	Heinz-Josef LENZ			
	Date Outilities	2. IVIAIGI 3	, 2000	Group Art Unit	1634			
(use as many sheets as necessary)				Examiner Name	Sitton, Jehanne Souaya			
Sheet	2	of	3	Attorney Docket Number	064189-0201 (2924)			

Cite No.¹	Foreign Patent Document Office ³ Number ⁴ Kind C	ode ⁵	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant	
		wn)		MM-DD-YYYY	Passages or Relevant Figures Appear	тв
5	WO 01/75175		University of Southern California	10-11-2001		
6	WO 2004/011625		University of Southern California	02-05-2004		
7	WO 2004/037852	A2	University of Medicine and Dentistry of New Jersey	05/04/2004		1
B	WO 2004/037852	A3	University of Medicine and	05/04/2004		
I			Dentistry of New Jersey			_
7		WO 2004/037852	WO 2004/037852 A2	WO 2004/011625 University of Southern California WO 2004/037852 A2 University of Medicine and Dentistry of New Jersey WO 2004/037852 A3 University of Medicine and	WO 2004/011625	WO 2004/011625 University of Southern 02-05-2004 California WO 2004/037852 A2 University of Medicine and Dentistry of New Jersey WO 2004/037852 A3 University of Medicine and 05/04/2004

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ*
.90	9	ELDER et al. "Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer." Clinical Cancer Res. April 2000, Vol. 6, pages 1378-1384.	
. [10	Fox et al. "Angiogenesis in normal tissue adjacent to colon cancer" <i>Journal of Surgical Oncology</i> (Dec. 1998) 69(4):230-234	
	11	IACOPETTA et al. "A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil" Brit. J. Cancer Sept. 2001, Vol. 85, No. 6, pages 827-830.	
	12	ISHIKAWA et al. *Dihydropyrimidien dehydorgenase activity and messenger RNA level may be related to the antitumor effect of 5-flurouracil on human tumor xenografts in nude mice* Clin. Cancer Res., April 1999, Vol. 5, pages 883-889.	
	13	Kuniyasu et al. "Induction of angiogenesis by hyperplastic colonic mucosa adjacent to colon cancer" American Journal of Pathology (Nov. 2000) 1575):1523-1535	
	14	LENZ et al. "A 6 base-pair deletion in the 3' UTR of the thymidylate synthase (TS) gene predicts TS mRNA expression in colorectal tumors: a possible candidate gene for colorectal cancer risk" PNAS, March 2002, Vol. 43, page 660 (abstract only).	
T	15	Liotta et al. "The microenvironment of the tumour-host interface" Nature (May 2001) 411(6835):375-379	

Examiner Signature	Jehanne	SHA	Date Considered	10/6/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ¹Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁴Applicant is to place a check mark here if English tanguage Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MODIFIED PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Par ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for	form 1449B	PTO	required to respond to a collection of information unless it contains a valid OMB c		
INFORMATION DISCLOSURE				Application Number	09/715,764	
STATEMENT BY APPLICANT				Filing Date	11/15/2000	
	Date Submitte	d: March 3	2006	First Named Inventor	Heinz-Josef LENZ	
	Date Coomitte	u. Walui J	, 2000	Group Art Unit	1634	
(use as many sheets as necessary)				Examiner Name	Sitton, Jehanne Souaya	
Sheet	3	of	3	Attorney Docket Number	064189-0201 (2924)	

Cite No. ¹ 16	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. PARK et al. "Thymidylate synthase gene polymorphism predicts response to capecitabine in advance colorectal cancer" Int. J. Colorectal Dis., Jan. 2002, Vol. 17, No. 1, pages 46-49. PULLARKAT et al. "Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy" Pharmacogenomics J., 2001, Vol. 1, No. 1, pages 65-70.	T
	colorectal cancer* Int. J. Colorectal Dis., Jan. 2002, Vol. 17, No. 1, pages 46-49. PULLARKAT et al. "Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU	
17	PULLARKAT. et al. "Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy" Pharmacogenomics J., 2001, Vol. 1, No. 1, pages 65-70.	
		l
18	SALONGA et al. "Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihycropyrimidien dehydrogenase, thymidylate synthase, and thymidine phosphorylase" Clin. Cancer Res., April 2000, Vol. 6, pages 1322-1327.	
19	SHIROTA et al. "ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy" J. Clin. Oncol., Dec. 2001, Vol. 19, No. 23, pages 4298-4304.	
20	polymorphism in the thymidylate synthase gene" Cancer Epidem., Biomarkers and Prevention, American Assoc. Cancer Res., Dec. 2000, Vol. 9, No. 12, pages 1381-1385.	
21	VILLAFRANCA et al. "Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer" J. Clin. Oncol., March 2001, Vol. 19, No. 6, pages 1779-1786.	
22	EP 03772163.6 Search Report dated 10/24/2005	
23	EP 03772163.6 Search Report dated 02/03/2006	
	20 21 22	 April 2000, Vol. 6, pages 1322-1327. SHIROTA et al. "ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy" J. Clin. Oncol., Dec. 2001, Vol. 19, No. 23, pages 4298-4304. ULRICH et al. "Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene" Cancer Epidem., Biomarkers and Prevention, American Assoc. Cancer Res., Dec. 2000, Vol. 9, No. 12, pages 1381-1385. VILLAFRANCA et al. "Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer" J. Clin. Oncol., March 2001, Vol. 19, No. 6, pages 1779-1786. EP 03772163.6 Search Report dated 10/24/2005

Examiner Signature	Jehanne	S:H~	Date Considered	10/6/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-